Page last updated: 2024-11-12

azamulin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

azamulin: a Cyp3A inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16072188
CHEMBL ID2103760
MeSH IDM0472391

Synonyms (22)

Synonym
sa-85530b
azamulin
tdm-85530
azamulinum
(3as,4r,5s,6r,8r,9r,9ar,10r)-6-ethyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propanocyclopentacycloocten-8-yl ((5-amino-1,2,4-triazol-3-yl)thio)acetat
azamulin [inn]
unii-875aq866x1
((5-amino-s-triazol-3-yl)thio)acetic acid, 8-ester with (3as,4r,5s,6r,8r,9r,9ar,10r)-6-ethyloctahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one
((5-amino-s-triazol-3-yl)thio)acetic acid, 8-ester with (3as,4r,5s,6r,8r,9ar,10r)-6-ethyloctahydro-5,8-dihydroxy-4,6,9,10-tetramethyl-3a,9-propano-3ah-cyclopentacycloocten-1(4h)-one
875aq866x1 ,
CHEMBL2103760
14-((5-amino-4h-1,2,4-triazol-3-yl)-thioacetoxy)-14-deoxy-19,20-dihydromutilin
azamulin, >=98% (hplc)
MWY ,
(3as,4r,5s,6r,8r,9r,9ar,10r)-6-ethyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl [(5-amino-1h-1,2,4-triazol-3-yl)sulfanyl]acetate
[(1s,2r,3s,4r,6r,7r,8r,14r)-4-ethyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(5-amino-1h-1,2,4-triazol-3-yl)sulfanyl]acetate
Q27269792
HY-W019847
CS-0031638
bdbm50569646
DTXSID301046434
AKOS040755667
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.24000.00011.753610.0000AID1759747
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1171222Ratio of MIC for wild-type tolC-deficient Escherichia coli in presence of 2% HSA to MIC for tolC-deficient Escherichia coli in presence of 2% HSA2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID318653Antibacterial activity against vancomycin-susceptible Enterococcus faecium ATCC 19434 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1171220Antibacterial activity against wild-type Staphylococcus aureus in presence of 2% HSA2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID589168Mechanism based inhibition of human cytochrome P450 3A52005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1171214Antibacterial activity against tolC-deficient Escherichia coli in presence of 2% HSA2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID318656Antibacterial activity against Haemophilus influenzae TH13 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1154672Antibacterial activity against methicillin-resistant Staphylococcus epidermidis at 320 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID318672Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith in mouse dosed twice iv 1 hr and 4 hrs after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1154671Antibacterial activity against methicillin-resistant Staphylococcus aureus at 160 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1154675Antibacterial activity against Escherichia coli at 160 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1171213Antibacterial activity against tolC-deficient Escherichia coli2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1154673Antibacterial activity against methicillin-resistant Staphylococcus epidermidis at 160 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID589113Mechanism based inhibition of human cytochrome P450 3A42005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1154667Antibacterial activity against methicillin-resistant Staphylococcus epidermidis after 48 hrs by agar dilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID318652Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1154670Antibacterial activity against methicillin-resistant Staphylococcus aureus at 320 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1154676Antibacterial activity against Streptococcus agalactiae at 320 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID318674Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 in mouse dosed twice iv 1 hr and 4 hrs after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318651Antibacterial activity against Streptococcus pyogenes ATCC 12344 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318673Antibacterial activity against methicillin-resistant Staphylococcus aureus KT0116 in mouse dosed twice iv 1 hr and 4 hrs after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1171215Antibacterial activity against wild-type Escherichia coli2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID1154668Antibacterial activity against Streptococcus agalactiae after 48 hrs by agar dilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1154674Antibacterial activity against Escherichia coli at 320 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID1154669Antibacterial activity against Escherichia coli after 48 hrs by agar dilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID318676Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith in po dosed mouse twice daily2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1759747Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins by LC/MS/MS analysis2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Design, synthesis and biological evaluation of novel pleuromutilin derivatives as potent anti-MRSA agents targeting the 50S ribosome.
AID1171219Antibacterial activity against wild-type Staphylococcus aureus2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID318645Antibacterial activity against methicillin-susceptible Staphylococcus aureus Smith by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318648Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318649Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318646Antibacterial activity against methicillin-resistant Staphylococcus aureus KT0116 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1154677Antibacterial activity against Streptococcus agalactiae at 160 ug/ml after 24 hrs by Oxford cup assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
AID318675Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KT2524 in mouse dosed twice iv 1 hr and 4 hrs after infection2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1741719Inhibition of CYP450 (unknown origin)
AID1171221Ratio of MIC for wild-type Staphylococcus aureus in presence of 2% HSA to MIC for wild-type Staphylococcus aureus2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
AID318655Antibacterial activity against Moraxella catarrhalis K1209 by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318654Antibacterial activity against vancomycin-resistant Enterococcus faecium KU1778 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318647Antibacterial activity against methicillin-resistant Staphylococcus aureus KMP9 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318644Antibacterial activity against methicillin-susceptible Staphylococcus aureus FDA 209P by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID318650Antibacterial activity against penicillin-resistant Streptococcus pneumoniae KT2524 clinical isolate by broth microdilution method2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
AID1154666Antibacterial activity against methicillin-resistant Staphylococcus aureus after 48 hrs by agar dilution method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's4 (28.57)24.3611
2020's5 (35.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.78 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]